Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Professionals Reference (MPR)
The FDA expanded approval of Capvaxive, a pneumococcal 21-valent conjugate vaccine, to children and adolescents aged 2 to 17 years with at least one chronic medical condition increasing pneumococcal disease risk, based on STRIDE-13 trial data showing noninferiority to PPSV23 across 12 shared serotypes and statistically significantly higher OPA GMTs for 9 serotypes unique to Capvaxive.
Ambulatory Care Pharmacy (BCACP) June 24th 2026
Psychiatry Advisor
Suicide mortality increased among adolescents and young adults across the Americas from 2000 to 2021. Rates varied by age, sex, and region, with widening disparities observed in population-level data.
Emergency Medicine June 23rd 2026
JNP: The Journal for Nurse Practitioners
A 14-year-old athlete presenting with exertional dyspnea and partial albuterol response prompted a structured biopsychosocial workup that revealed anxiety disorder rather than exercise-induced asthma as the primary driver.
Adolescent Medicine June 18th 2026
Pulmonology Advisor
The GINA 2026 update introduces age-stratified primary care flowcharts for asthma exacerbation management, expands biologic guidance including depemokimab, and adds a formal red-flag list for fatal or near-fatal asthma risk in adults and adolescents.
Adolescent Medicine June 17th 2026
Clinical Infectious Diseases (CID)
A retrospective quasi-experimental study at St. Jude Children’s Research Hospital found that discontinuing empiric antibiotics within 72 hours of febrile neutropenia onset in clinically stable pediatric haploidentical HCT recipients reduced antibiotic exposure by a median of 8 days without significant differences in bloodstream infection, ICU admission, or mortality.
Pediatric Hematology/Oncology June 17th 2026
The Journal of Clinical Endocrinology & Metabolism (JCEM)
A JCEM clinical guidance article outlines a two-criterion diagnostic standard for adolescent PCOS, requiring both persistent hyperandrogenism and menstrual irregularity, and frames adolescence as the critical window for metabolic and psychosocial risk stratification.